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delivery modes. Any harm caused by nicotine replace-
ment must be compared with that caused by continued
smoking—which is extremely harmful to both the
woman and her child. Clear evidence of effectiveness
and safety is required. We need definitive randomised,
placebo controlled, clinical trials of a range of doses and
administration routes for nicotine replacement in preg-
nancy.
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Making public health interventions more
evidence based
TREND statement for non-randomised designs will make a difference
The movement towards evidence based publichealth policy has been gaining momentumover the past decade. It takes an important step
forward with the recent publication of the TREND
statement (transparent reporting of evaluations with
non-randomised designs).1 Its aim is to improve the
quality of reporting of non-randomised evaluations so
that the conduct and findings of such research are
transparent and information that is critical for research
synthesis is not missing, and to do for public health
evaluations what the CONSORT statement has done
for randomised controlled trials.2
The publication of the TREND statement reflects
the increasing recognition that successful evaluation of
public health interventions will necessarily entail the
use of research designs other than controlled trials3–5
and various types of evidence, often in combination.4 6
The reasons for using such interventions include the
following.
Firstly, the intervention is already well established
or its delivery is by nature widespread—for example,
evaluation of the efficacy of BCG in different settings3
or of the current advertisement campaign in the
United Kingdom to encourage adherence to speed
limits in built up areas. No control groups exist; the
evaluations need to be based on comparisons before
and after the intervention and on comparisons of
adopters with non-adopters.
Secondly, the intervention has been shown to be
efficacious or effective in small scale studies, conducted
under ideal conditions, but its effectiveness needs to be
shown when scaled up and carried out under routine
conditions.6
Thirdly, the intervention is multifaceted and the
pathways to impact are complex. Victora et al argue that
an impact achieved in randomised controlled trials will
not convince policy makers unless it is accompanied by
additional evidence showing changes in intermediate
process outcomes and differences between adopters and
non-adopters of the intervention.6
Fourthly, ethical issues in the use of a control group,
such as occurs when the intervention has known
benefits but its efficacy against an important outcome is
not known, or when patient choice needs to be factored
in.7 This issue was overcome in the Gambia hepatitis B
vaccine trial of the long term impact on liver cancer, by
using a “stepped wedge design,” with the vaccine
introduced district by district on a staggered basis and
the order of introduction chosen at random.8
The TREND statement follows the exact format of
the revised CONSORT statement, retaining the same 22
items, with revised descriptions relevant to non-
randomised designs. Some important enhancements
have been made that are also relevant to randomised
controlled trials evaluating public health interventions.
Item 2 (background) now includes the underlying
behavioural or social science theory used to develop the
intervention, and item 4 (interventions) encourages a
more detailed description of both the content and the
delivery of the intervention.
The authors’ vision is that adoption of the TREND
reporting guidelines will ensure that comparable
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information across studies can be consolidated and
translated into generalisable knowledge and practice
more easily.1 Have they got it right?
The answer is both yes and no. The authors rightly
say that this is work in progress and that improvements
might be necessary. With this publication they aim to
start a dialogue; they invite comments and feedback.
Their decision to follow rigidly the 22 items of the
CONSORT statement is a major limitation—this is not a
case where one size fits all. Although I strongly endorse
the suggestion that alternative ways, such as linked web
pages, are needed to tackle fully the level of detail
needed if an intervention is to be reproducible,9 I
encourage a rethink and expansion to include named
items relating to the development of interventions, and
additional items for process and confounding variables.
I would also redo item 8 (renamed assignment method),
which attempts to capture the evaluation design used.
This is the weakest part of the TREND statement, and it
needs to be expanded to capture the whole range of
evaluation designs; at present it is biased towards the
evaluation of newly introduced interventions. I recom-
mend an entry called evaluation design, including sepa-
rate items for the twomain dimensions4: comparisons to
be used (before and after, adopters v non-adopters,
intervention v control and whether randomised or not,)
and design of data collection (longitudinal, cross
sectional, case-control).
However, this is an excellent and encouraging start
and an important milestone in public health research.
Having the TREND statement of agreed reporting
standards for non-randomised designs increases their
scientific credibility and draws attention to the
scientific rigour involved in their conduct and design. It
should challenge the prejudice that evaluation
research is second rate and encourage more to do such
research. We should look forward to its continuing
development and evaluation.
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Pathogenesis and treatment of varicoceles
Controversy still surrounds surgical treatment
The varicocele is an enigma in the treatment ofmale infertility. Despite over 30 years of evidencethat repair of varicoceles results in improved fer-
tility,1 the retrospective nature of most of these reports
has led to controversy regarding the utility of treatment.
This is compounded by the fact that not all varicoceles
cause infertility. Varicocele is present in approximately
15% of men, and, although it is the most commonly
diagnosed cause of male infertility, nearly two thirds of
men with varicoceles remain fertile. The reason for this
discrepancy remains unknown, although it is postulated
that the cause of infertility is related to both temperature
and time.2 The anatomical and physiological principles
of the testicular vasculature and the evidence base
regarding surgical treatment are outlined here.
The blood supply to the testis, as well as the resulting
counter current heat exchange, results in cooler intrates-
ticular temperatures compared with body temperature.3
Disruption of this system can result in hyperthermia of
the testes.4 As the left side drains into a system with
higher resistance, small venules may persist or open
during embryogenesis. Testicular blood flow remains
low before puberty, and therefore these veins do not
become clinically apparent until adolescence when
testicular blood flow increases, which explains the
appearance of most varicoceles around puberty.5 Endo-
crine dysfunction may contribute to varicocele related
infertility. Studies have shown altered function of the
Leydig, Sertoli, and germ cells in men with notable vari-
coceles.6 Whether this is due to the increased
intratesticular temperature or other factors is unknown.
Treatments vary from radiological ablation to
surgical ligation of the varicocele, although most
urologists reserve the radiological approach for the
rare surgical failures. Numerous studies have examined
various operative methods, attempting to show a
difference in efficacy and outcome. Although most of
these methods result in similar short term results, the
open microsurgical methods tend to yield fewer long
term complications, such as recurrences and hydro-
celes.7 Although laparoscopic varix ligation was once
touted as a minimally invasive method compared with
open surgical repair, several authors have shown simi-
lar recovery rates, equal efficacy, fewer complications,
and the advantage of not having to enter the
abdomen.7 Most experts agree that only clinically
apparent varicoceles should be treated. Although sub-
clinical varicoceles (those identified by imaging studies
only) may result in improvement in some seminal vari-
ables, evidence of efficacy is lacking regarding
pregnancy rates.8
A Cochrane review identified five randomised con-
trolled trials that examined the outcomes in couples
with male factor infertility and varicoceles and
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